DNER and neoplasm: Inspired by the application of aptamers in targeted tumor therapy, in 2021 Sheng group designed and synthesized the first Aptamer-PROTAC conjugate (APC) by combining the aptamer with the BET protein degrader.516 They used a disulfide bond to connect the effective BET (BRD4) degrader and the nucleoside-dependent aptamer AS to synthesize the APC 254 (APR-Cy3, Fig. 83).